Article summary
This post-hoc analysis of a randomised, double-blind trial (n=74) compared three IV esketamine infusions (17.5mg/70kg) with midazolam alongside ongoing antidepressants in adolescents with depression. Drug-by-time interactions for anhedonia favoured esketamine from Day 12, but only the Day 19 group comparison survived correction for multiple comparisons. The interaction was no longer significant after accounting for overall depression severity.
Continue to the original publication for the complete article.